Home > Newsletters > FDAnews Drug Daily Bulletin > Impax Can Launch Generic Renvela, Renagel in 2014 Following Genzyme Settlement
FDAnews Drug Daily Bulletin
Sept. 6, 2012 | Vol. 9 No. 175
Impax Can Launch Generic Renvela, Renagel in 2014 Following Genzyme Settlement
Impax Laboratories can market generic versions of Genzyme’s kidney disease drugs Renvela and Renagel in 2014 under a settlement with the brand drugmaker. Genzyme has granted Impax a license to sell a generic version of Renvela (sevelamer carbonate) 800-mg tablets beginning March 16, 2014, Impax said Tuesday. Impax can also sell oral suspension versions of Renvela and Renagel (sevelamer hydrochloride) beginning Sept. 16, 2014.
Drug Industry Daily
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.